Lurasidone

Lurasidone, sold under the brand name Latuda, is a medication. It is an atypical antipsychotic medication that is used to treat schizophrenia and bipolar depression. It is taken by mouth. It was first approved for medical use in the United States in 2010. In 2013, it was approved in Canada and by the U.S. Food and Drug Administration (FDA) to treat bipolar depression.

Lurasidone Media

ID-14283, the main active metabolite. The hydroxylation of the norbornane ring is highlighted. The other active metabolite, ID-14326, has the OH group in endo position.
The main inactivation step by oxidative N-dealkylation produces the metabolites ID-11614 and ID-20219.
Latuda 40mg and 80mg bottles with 80mg tablets.

This short article about chemistry can be made longer. You can help Wikipedia by adding to it.